Loading
A phase 1/2 trial of Afuresertib and Lapiteronel run by Laekna Limited, completed.
Dose-Escalation and Efficacy Study of LAE001/Prednisone Plus Afuresertib Patients With m-CRPC is a phase 1/2 interventional study registered as NCT04060394 by Laekna Limited, with 49 participants enrolled, started 2019-09-13, primary completion reached 2023-12-27. Conditions recorded: Metastatic Castration-resistant Prostate Cancer. Interventions recorded: Phase I and Phase II: LAE001/prednisone + afuresertib.
Shares Lapiteronel, Laekna Therapeutics and the tag pipeline.
Shares Afuresertib, Laekna Therapeutics and the tag pipeline.
Shares Afuresertib, Laekna Therapeutics and the tag pipeline.
Shares Afuresertib, Laekna Therapeutics and the tag pipeline.
Shares Afuresertib, Laekna Therapeutics and the tag pipeline.
Shares Laekna Therapeutics and the tag pipeline.
Shares Laekna Therapeutics and the tag pipeline.
Shares Metastatic castration-resistant prostate cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/